系统性红斑狼疮患者血浆可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平。
Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
机构信息
First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
出版信息
Biomarkers. 2012 Dec;17(8):758-63. doi: 10.3109/1354750X.2012.728623. Epub 2012 Oct 4.
OBJECTIVE
Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker of systemic inflammation. We aimed to characterize plasma suPAR levels in SLE patients.
METHODS
We measured plasma suPAR, C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in 89 SLE patients and 29 healthy controls.
RESULTS
suPAR and ESR values were higher in SLE than in controls, while CRP levels were comparable. ROC analysis of suPAR levels indicated a cut-off value of 5.70 ng/mL to distinguish patients with high disease activity (SLEDAI >8).
CONCLUSION
suPAR might be an objective marker for identifying SLE patients with active disease.
目的
可溶性尿激酶型纤溶酶原激活物受体（suPAR）是全身炎症的生物标志物。本研究旨在对系统性红斑狼疮（SLE）患者的血浆 suPAR 水平进行特征描述。
方法
我们测量了 89 例 SLE 患者和 29 例健康对照者的血浆 suPAR、C 反应蛋白（CRP）和红细胞沉降率（ESR）。
结果
SLE 患者的 suPAR 和 ESR 值高于对照组，而 CRP 水平相当。suPAR 水平的 ROC 分析表明，区分疾病活动度高（SLEDAI＞8）的患者的截断值为 5.70ng/mL。
结论
suPAR 可能是一种客观标志物，可用于识别疾病活动度高的 SLE 患者。
Zotero 插件